Background

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an estimated prevalence rate ranging from 0.4% to 1% in the general population. It is associated with a 5- to 6-fold increase in the risk of cerebrovascular events and is the leading cause of ischemic strokes.[4] Asymmetric dimethylarginine (ADMA), an analogue of L-arginine, is a naturally occurring product of metabolism found in human circulation. Elevated levels of ADMA can inhibit nitric oxide synthase (NOS) and lead to endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases.[5,6] High plasma ADMA levels have been reported to be an independent risk factor for adverse cardiovascular events and mortality in patients with coronary artery disease (CAD),[7] chronic kidney disease,[8] and after acute ischemic stroke.[9] Recently, several studies have shown that ADMA levels are high in AF patients,[10,11] and are associated with a higher recurrence rate after cardioversion or catheter ablation for AF.[12,13] However, the data regarding the relationship between ADMA and adverse events in AF patients are limited. Thus, the goal of the present study was to investigate whether the plasma levels of ADMA are a predictor of poor clinical outcomes in patients with AF.

Methods

Ethics Statement

The study protocol was approved by the Institutional Review Board at Taipei Veterans General Hospital and informed written consent was obtained from each participant in accordance with the ethical guidelines of the Declaration of Helsinki.
Study Population
From July 2006 to June 2009, we enrolled 990 individuals who were referred to our institution for coronary angiography. Among these patients, 141 subjects with a diagnosis of AF, including 52 paroxysmal AF (PAF) and 89 non-paroxysmal AF (non-PAF) patients, were identified as the study population.[14,15] Blood samples were collected before diagnostic coronary angiography, which was then performed using a standard procedure. The CHA2DS2-VASc score was calculated for each AF patient based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack, or an age ≥75 years, and 1 point is assigned for each of the following factors: age 65–74 years, a history of hypertension, diabetes, recent cardiac failure, vascular disease (CAD, myocardial infarction, complex aortic plaque, or peripheral artery disease), and female sex.[16] Percutaneous coronary intervention or coronary artery bypass surgery was recommended for patients if significant CAD was diagnosed, which was defined as the presence of ≥50% stenosis in at least one major coronary artery according to the results of coronary angiography.

Laboratory Measurement of ADMA
Before performing coronary angiography, blood samples were collected into tubes containing ethylenediaminetetraacetic (EDTA) as an anticoagulant and were centrifuged at 3000 rpm for 10 minutes at 4°C immediately after collection. Plasma samples were kept frozen at −70°C until analysis. Plasma ADMA concentrations were determined by high performance liquid chromatography using precolumn derivatization with o-phthaldialdehyde as previously described.[17] The recovery rate for ADMA was >90%, and the within-assay and between-assay variation coefficients were not greater than 7% and 8%, respectively.

Definitions of the Clinical Endpoints and Follow-up
Patients were prospectively followed by the office visit monthly or by telephone contact and chart review for the occurrence of adverse events, defined as ischemic stroke or cardiovascular death. Ischemic stroke was defined as a focal neurological deficit of sudden onset as diagnosed by a neurologist, lasting >24 hours, and caused by ischemia. Imaging studies of brain, including computed tomography scan or magnetic resonance imaging, were performed for each patient to exclude the presence of intra-cranial hemorrhage and confirm the diagnosis. Cardiovascular death was diagnosed as any death with definite cardiovascular cause or any hemorrhage and confirm the diagnosis. Cardiovascular death was performed for each patient to exclude the presence of intracranial computed tomography scan or magnetic resonance imaging, were angiography.

Laboratory Measurement of ADMA

Study Population

Main Findings
The main findings of the present study were as follows: (1) ADMA levels were higher in AF patients than non-AF patients. Moreover, non-PAF patients had higher ADMA levels than PAF patients. (2) A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score.

Increased Level of ADMA in AF – Is it a cause or a result?
Several previous studies have investigated the association between the levels of ADMA and AF.[10,11] Cengel et al. demonstrated that the plasma concentration of ADMA was

Statistical Analysis
The data are presented as mean values and standard deviations for normally distributed continuous variables, medians and interquartile ranges for skewed data, and proportions for categorical variables. The differences between normally distributed continuous values were assessed using an unpaired two-tailed t-test or one-way analysis of variance (ANOVA) with post-hoc Bonferroni test. The Mann-Whitney rank-sum test was used for the analysis of skewed variables, and the differences between nominal variables were compared with a chi-squared test. A Cox regression analysis was used to identify the factors associated with adverse events. The optimal cut-off value of the ADMA levels in the prediction of adverse events was identified using the receiver operating characteristic (ROC) curve. The event-free survival curve was plotted using the Kaplan-Meier method with statistical significance examined by the log-rank test. All statistical signifi-
cances were set at p<0.05 and all statistical analyses were carried out by SPSS 17.0 (SPSS Inc. USA).

Results

Baseline Characteristics and ADMA Levels
The mean age of the study population (AF patients, n = 141) was 79.3±4.2 years (range, 58–89 years), and 90.8% of them were male. Hypertension was the most common comorbidity, which was present in 81.6% of all patients. The mean left atrial (LA) diameter and left ventricular ejection fraction (LVEF) were 39.1±7.1 mm and 49.8±12.2%, respectively. Significant CAD was present in 89 patients (63.1%), and most of them (87 patients) received coronary interventional procedures. The ADMA levels were higher in AF patients than in non-AF patients (0.50±0.13 versus 0.45±0.07 μmol/L; p<0.001). In addition, non-PAF patients had higher ADMA levels than PAF patients (0.52±0.15 versus 0.48±0.08 μmol/L; p<0.001) (Figure 1). Besides, plasma ADMA levels were significantly higher in patients with significant CAD (≥50% stenosis, n = 639) than those with insignificant CAD (20–50% stenosis, n = 282) and normal coronary artery (<20% stenosis, n = 69) (0.47±0.10 versus 0.44±0.09 versus 0.42±0.08 μmol/L, p<0.001).

Predictors of Adverse Events
During the follow-up period of 30.7±14.4 months, 21 patients (14.9%) experienced adverse events, including cardiovascular death in 7 patients and ischemic stroke in 14. The baseline characteristics of patients with and without events are shown in Table 1. Patients with adverse events had lower body mass index (BMI), larger LA diameters, lower LVEF, higher ADMA levels, and higher CHA2DS2-VASc scores than patients without events. Significant predictors of adverse events based on the univariate Cox regression analysis are shown in Table 2. The ADMA level, CHA2DS2-VASc score, and LA diameter remained as independent predictors of adverse events in the multivariate model (Table 3). When we only adjusted ADMA and history of vascular disease in the regression model, the level of ADMA was still a significant predictor of adverse events with an adjusted hazard ratio of 1.456 per 0.1 μmol/L increment (95% confidence interval = 1.182–1.795, p<0.001).

Figure 2 shows the ROC curve for predicting events based on the ADMA levels. At a cutoff value of 0.55 μmol/L identified by the ROC curve, the Kaplan-Meier survival analysis showed that patients with an ADMA level ≥0.55 μmol/L (sensitivity = 57.1%; specificity = 81.7%) were associated with a higher event rate compared to patients with an ADMA level <0.55 μmol/L (33.3% versus 9.3%, p = 0.001) during the follow-up period (Figure 3).

Discussion

Main Findings
The main findings of the present study were as follows: (1) ADMA levels were higher in AF patients than non-AF patients. Moreover, non-PAF patients had higher ADMA levels than PAF patients. (2) A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score.

Increased Level of ADMA in AF – Is it a cause or a result?
Several previous studies have investigated the association between the levels of ADMA and AF.[10,11] Cengel et al. demonstrated that the plasma concentration of ADMA was
significantly increased in AF patients compared to that of healthy controls.[10] This finding was further confirmed in the study performed by Goette et al. which enrolled 35 AF and 25 non-AF subjects, and demonstrated that ADMA levels were higher in AF patients compared to sinus rhythm patients.[11] However, the question that remains is if the increased ADMA levels are a cause or result in AF? Liu et al. demonstrated that AF could increase the expression of protein arginine methyltransferase-1 (PRMT-1), which would lead to an increased ADMA concentration.[18,19] The previous study also showed that ADMA levels decreased to normal values within 24 hours after AF was terminated by electrical cardioversion. These observations suggest that the higher ADMA levels may be a consequence of AF.[11] On the other hand, ADMA was recently demonstrated to have cytokine-like properties by activating polymorphonuclear neutrophils and enhancing the release of myeloperoxidase, which may increase systemic inflammatory burden and play an important role in the pathogenesis of AF.[20] In addition, increased serum ADMA concentrations were reported to be associated with a higher rate of AF recurrence after catheter ablation or electrical cardioversion in patients with persistent AF.[13,21] These findings may imply that ADMA itself might participate in the process of atrial remodeling and result in the occurrence of AF.

Based on the previous findings described above, we hypothesized that the increased ADMA levels may predispose patients to AF, which could further increase the concentration of ADMA and form a vicious cycle. The results of our study support this hypothesis. The observation of higher ADMA levels in PAF patients compared to non-AF patients suggest that ADMA is a cause of AF, and the further increased ADMA levels in non-PAF patients imply that sustained AF could result in an increased concentration of ADMA.

**ADMA and Adverse Events in AF**

AF patients constitute a high-risk population for cardiovascular events and mortality, and the risk varies according to several demographic and clinical characteristics, such as heart failure, hypertension and diabetes mellitus. Recently, a newly developed scoring system, the CHA2DS2-VASc score, which extends the CHADS2 scheme by considering additional stroke risk factors (vascular diseases and female gender), was recommended for guiding antithrombotic therapies for AF patients.[15,16] In
addition to the clinical risk score, several biomarkers, including cardiac troponin T, interleukin-6, and plasma von Willebrand factor, were reported to be useful in predicting adverse events in AF.[22,23] In the present study, we demonstrated that an increased level of ADMA may be a risk factor of poor prognosis for AF patients even after adjustment with the CHA2DS2-VASc score. This finding is consistent with a previous report showing that increased ADMA levels were present in patients with acute cardio-embolic infarction compared to controls.[24]

What is the mechanism behind the usefulness of ADMA in predicting adverse events in AF? By inhibiting the formation of endothelial nitric oxide (NO), ADMA accumulation in AF may result in endothelial dysfunction in LA and the LA appendage, which may lead to thrombus formation and subsequent thromboembolic events.[18] In addition to being a vasodilator, NO also inhibits platelet adhesion and aggregation, attenuates monocyte infiltration, suppresses myointimal hyperplasia and reduces oxidative stress.[25] The decrease in NO availability could therefore enhance atherosclerosis and local inflammation of the vessel wall, which may play an important role in plaque rupture, thereby leading to stroke or myocardial infarction.[26] Furthermore, previous studies have also shown that the infusion of ADMA in healthy volunteers would increase arterial stiffness and decrease cerebral perfusion.[27,28] Taken together, these evidences suggest

| Variable                                      | With events (n = 21) | Without events (n = 120) | P value |
|-----------------------------------------------|---------------------|--------------------------|---------|
| Age, years                                    | 81.5±3.8            | 79.0±4.1                 | 0.010   |
| Gender (male)                                 | 95.2%               | 90.0%                    | 0.391   |
| Smoking                                       | 14.3%               | 12.5%                    | 0.525   |

Table 1. Baseline characteristics of the patients with and without adverse events.

| Medical history (components of the CHA2DS2-VASc scoring system) | With events (n = 21) | Without events (n = 120) | P value |
|------------------------------------------------------------------|---------------------|--------------------------|---------|
| Congestive heart failure                                        | 66.7%               | 31.7%                    | 0.002   |
| Hypertension                                                    | 76.2%               | 82.5%                    | 0.337   |
| Diabetes mellitus                                               | 42.9%               | 36.7%                    | 0.589   |
| Previous stroke/TIA                                            | 19.0%               | 5.0%                     | 0.042   |
| Vascular disease*                                               | 100%                | 72.5%                    | 0.002   |
| Significant CAD diagnosed by angiography                        | 61.9%               | 63.3%                    | 0.900   |

Coronary interventional procedures

| Undergoing PCI                                                  | 52.4%               | 55.8%                    | 0.769   |
| Undergoing bypass surgery                                       | 4.8%                | 6.7%                     | 0.601   |
| Use of anti-platelet agents                                     | 100%                | 100%                     | 1       |
| Use of warfarin                                                 | 19.0%               | 20.0%                    | 0.593   |
| Body mass index (kg/m²)                                         | 23.2±4.2            | 25.3±3.4                 | 0.016   |
| Left atrial diameter, mm                                        | 42.4±5.8            | 38.6±7.1                 | 0.002   |
| LVEF, %                                                         | 44.7±13.6           | 50.7±11.7                | 0.038   |
| AF type (paroxysmal AF)                                         | 38.1%               | 36.7%                    | 0.90    |
| CHA2DS2-VASc score, median (inter-quartile range)               | 5 (4–6)             | 4 (4–5)                  | 0.010   |

ADMA level (μmol/L)                                              | 0.62±0.19           | 0.48±0.11                | 0.004   |

ADMA = asymmetric dimethylarginine; AF = atrial fibrillation; CAD = coronary artery disease; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; TIA = transient ischemic attack.

*In addition to history of myocardial infarction, complex aortic plaque, or peripheral artery disease, patients with significant CAD diagnosed by coronary angiography at the enrollment were also classified as having vascular disease, and assigned 1 point for calculating the CHA2DS2-VASc score.

doi:10.1371/journal.pone.0071675.t001

Table 2. Univariate Cox regression analysis for predictors of adverse events.

| Variables                          | Hazard ratio | 95% CI     | P value |
|------------------------------------|--------------|------------|---------|
| Body mass index (per kg/m²)        | 0.847        | 0.744–0.965| 0.012   |
| Left atrial diameter (per mm)      | 1.058        | 1.010–1.109| 0.018   |
| LVEF (per percent)                 | 0.964        | 0.931–0.997| 0.035   |
| CHA2DS2-VASc score                 | 1.936        | 1.282–2.923| 0.002   |
| ADMA level (per 0.1 μmol/L)        | 1.546        | 1.257–1.902| <0.001  |

ADMA = asymmetric dimethylarginine; LVEF = left ventricular ejection fraction.
doi:10.1371/journal.pone.0071675.t002

Table 3. Multivariate Cox regression analysis for predictors of adverse events.

| Variables                          | Hazard ratio | 95% CI     | P value |
|------------------------------------|--------------|------------|---------|
| Body mass index (per kg/m²)        | 0.931        | 0.821–1.056| 0.267   |
| Left atrial diameter (per mm)      | 1.081        | 1.022–1.143| 0.007   |
| LVEF (per percent)                 | 0.987        | 0.945–1.030| 0.540   |
| CHA2DS2-VASc score                 | 1.599        | 1.047–2.440| 0.030   |
| ADMA level (per 0.1 μmol/L)        | 1.364        | 1.072–1.736| 0.012   |

ADMA = asymmetric dimethylarginine; LVEF = left ventricular ejection fraction.
doi:10.1371/journal.pone.0071675.t003
that ADMA might be the potential link between AF, increased oxidative stress, endothelial dysfunction, thrombogenesis and atherosclerosis, and could therefore represent a risk factor of adverse events in AF patients.

Another interesting finding of the present study was that patients with a higher BMI had a lower event rate. The potentially protective effect of increased BMI in AF has been reported previously and termed the “obesity paradox”. The possible explanation is that there were more patients with heart failure in the group with events, and “cardiac cachexia” may predispose patients to a poor prognosis. The speculation is further supported by the finding that BMI was not a significant predictor of adverse events after the adjustment for other factors, including LVEF, LA diameter and the CHA2DS2-VASc score, which includes heart failure in the scoring scheme.

Comparison with Previous Studies

Compared to previous studies investigating AF, ADMA and cardiovascular risk, the patient number in our study was larger than that of previous ones. We specifically analyzed the ADMA levels in PAF and non-PAF patients, which could provide a further evidence to suggest that ADMA may involve in the process of AF progression. Besides, the relationship between ADMA and adverse events in pure AF patients, especially when considering CHA2DS2-VASc score, has not been explored before. To the best of our knowledge, the present study is the first one to demonstrate the significant link between ADMA and a poor prognosis in AF.

Study Limitations

There were several limitations of the present study. First, the study patients were enrolled from a population undergoing diagnostic coronary angiography and had a high prevalence of CAD. Besides, a high percentage of study patients (90.8%) were male. Whether the results presented here could be applied to other populations remained uncertain. Second, oral anticoagulants were underused for stroke prevention in our cohort due to the concern of high risk of bleeding (old age and concurrent use of anti-platelet agents). However, this is a common problem in managing AF patients in daily clinical practice. Besides, the use of warfarin was not a significant factor associated with adverse events in the Cox regression analysis, and therefore it may not confound the results demonstrating the usefulness of ADMA in predicting adverse events.
adverse events. Lastly, there were no low-risk patients with a CHA2DS2-VASc score of 0 or 1 enrolled in the present study. Therefore, we were not able to analyze whether the measurement of ADMA levels could be helpful in identifying patients at risk among these low-risk patients. The accumulated evidence shows that CHA2DS2-VASc score is better than the CHADS2 score in identifying patients who develop stroke and thromboembolism.[33,34] and it has expanded the indication for oral anticoagulants in AF patients.[35] It deserves a large-scale and prospective trial to confirm our findings and investigate whether ADMA could potentially refine the clinical risk stratification and improve decision-making for thromboprophylaxis in patients with AF.

Conclusions

ADMA levels were found to be higher in AF than non-AF patients. Furthermore, non-PAF patients had higher ADMA levels than PAF patients. A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHADS2-VASc score in this high-risk and male predominant population with a high prevalence of CAD. The potential role of plasma ADMA levels in predicting adverse events in addition to the CHA2DS2-VASc score deserves further investigation.

Author Contributions

Conceived and designed the experiments: T-FC T-ML. Performed the experiments: T-ML T-CT. Analyzed the data: T-FC Y-JL H-MT S-LC S-AC. Contributed reagents/materials/analysis tools: L-WL Y-FH T-CT M-HH. Wrote the paper: T-FC T-ML M-HH S-AC.

References

1. Go AS, Hylek EM, Phillips KA, Chang Y, Hershfield LE, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2750–2757.
2. Camm AJ, Lip GY, Gatteschi JL, Laupacis A, Krousal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155: 469–473.
3. Potpara TS, Lip GY (2011) Lone atrial fibrillation: what is known and what is to come. Int J Clin Pract 65: 446–457.
4. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983–988.
5. Borer RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Am Med 38: 126–156.
6. Sibai L, Agarwal SG, Home PD, Borer RH (2010) The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Circ Cardiol Rev 6: 82–90.
7. Schnabel R, Blankenberg S, Lackner KJ, Rupprecht HJ, et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtherosGene Study. Circ Res 97: 53–59.
8. Lu TM, Chong MY, Lin CC, Hsu CP, Lin SJ (2011) Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 6: 1566–1572.
9. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, et al. (2010) Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208: 518–523.
10. Cheng A, Solomon L, Helms I, Masa J, et al. (2012) The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 154: 141–146.
11. Xu W, Yin Z, Li J, Song Y, Qu X (2009) Effects of resusvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 32: 2024–2029.
12. Jia SJ, Jiang BJ, Hu CP, Zhang XH, Deng HW, et al. (2006) Lysephosphatidylincholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vascular Pharmacol 44: 145–148.
13. von Leitner EC, Klinke A, Arzler D, Slocum JL, Lund N, et al. (2011) Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 124: 2734–2745.
14. Xia W, Qu X, Yu Y, Zhang X, Feng W, et al. (2008) Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol 31: 1036–1040.
15. Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, et al. (2011) Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 57: 2496–2504.
16. Roldan V, Marin F, Diaz J, Gallego P, Jover E, et al. (2012) High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 10: 1500–1507.
17. Wandwy, Teerlink T, Brudin L, Brudinl M, Nilsson I, et al. (2006) Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185: 271–277.
18. Boge RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59: 824–833.
19. van der Wal AC, Becker AE, van der Loos CM, Das PK (1994) Site of initial rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36–44.
20. Achan V, Broadhead M, Malaki M, Whaley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455–1459.
21. Kielstein JT, Donnerstag F, Gallego P, Meune J, Kielstein A, et al. (2006) ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37: 2024–2029.
22. Badheka AO, Rathod A, Khashab MA, Garg N, Mohamad T, et al. (2010) Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 123: 646–651.
23. Ardestani A, Hoffman JJ, Cooper HA (2010) Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol 106: 369–373.
24. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 125: 636–645 e634.
25. Chan PS, Maddox TM, Tang F, Sperner S, Sperts JA (2011) Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PCI Scorecard program). Am J Cardiol 108: 1136–1140.
26. Van Staa TP, Sirkeci E, Di Tanna GL, Lane DA, Lip GY (2011) A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 9: 39–48.
27. Frijberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischemic stroke and bleeding in 102,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33: 2719–2747.